KORU Medical Systems

Q2 2026 Earnings Call

August 5, 2026

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements.

Forward-looking statements discuss the Company's current expectations and projections relating to its plans, objectives, future performance, business, outlook and financial projections. Forward-looking statements can be identified by words such as "vision", "expected", "estimated", "plan", "drivers", "path", "milestones", "opportunities" and "outlook", and include without limitation timing of international expansion, existence and timing of pharma trials, financial guidance for 2026, long-term financial goals, and timing of 510(k) and global submissions. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those associated with inflation, tariffs, war and other geopolitical conflicts, customer ordering patterns, availability and costs of raw materials and labor and our ability to recover such costs, future operating results, growth of new patient starts and the Ig market, our compliance with Food and Drug Administration and foreign authority regulations and the outcome of regulatory audits, introduction and adoption of competitive products, acceptance of and demand for new and existing products, ability to penetrate new markets, success in enforcing and obtaining patents, reimbursement related risks, government regulation of the home health care industry, success of our research and development effort, expanding the market of FREEDOMTM System, demand in the SCIg market, availability of sufficient capital if or when needed, dependence on key personnel, and the impact of recent accounting pronouncements, as well as those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, which is on file with the SEC and available on our website at www.korumedical.com/investors. All information provided in this release and in the attachments is as of August 5, 2026, unless otherwise indicated. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

Revenues: All references to revenue(s) in this presentation refer to net revenues.

Global Leader in Large-Volume Subcutaneous Drug Delivery

Capitalizing on the ongoing shift from IV hospital settings to **subcutaneous therapy in the home** and in **infusion clinics**

KORU Freedom Infusion System is, today, primarily used by **~60,000 chronic, recurring** subcutaneous immunoglobulin (SCIg) drug therapy patients

Expanding our market beyond SCIg via 8 current pipeline drugs to bring **new therapies** onto our label

Simple, trusted mechanical system with foundational capability to lead drug delivery market in shift towards **connected health solutions**

Easy to Use, Differentiated Infusion Devices

Q2 2026 Results

Second Quarter Performance Highlights

Revenue: $12M

18% growth over prior year period

Gross Margin: 65.1%

Raising FY guidance from 61-63% to 62-64%

Net Income: $0.3M

222% improvement over prior year period

Strategic Vision Intact: Progress Across Growth Pillars

KORU's Strategic Growth Pillars

1 Protect and Grow our Core Domestic Business

- 12% y/y growth
- SCIg **recurring revenue base** paired with continuous market share gains
- **Outpacing underlying market** growth[1]
- **RYSTIGGO®** validating value proposition in delivering non-Ig therapies

2 Expand Internationally

- 59% y/y growth
- Vial to **PFS conversion**; key EU markets coming online in 2026
- Navigating **specific regional launch dynamics** extends timeline for full roll-out from 2H26 into 2027
- Confident in market opportunity with **runway for further penetration**

3 Enable More Drugs, Reach More Patients

- 8 non-Ig **drugs in pipeline**
- Pipeline collaborations serve as **growth engine for non-Ig strategy**
- **Long-term partnership with Biogen/Apellis**; near-term trial timing may shift with acquisition integration

Technology Asset Investment to enhance and differentiate KORU Platform

1. Third Party Data on File

Q2 2026 Results

Strategic Updates

Connected Monitoring Technology Acquisition

Real-time data insights for pharma and specialty pharmacy partners

Secondary Immunodeficiency (SID)

Opportunity to access large patient base; large pharmas progressing trials with potential endpoints over next 12-18 months

U.S. Oncology Strategy

Withdrawing Phesgo® 510(k) submission to prioritize alternative biologics with higher volumes; Continuing to pursue Phesgo® internationally

Deferoxamine 510(k)

510(k) submitted at end of Q1 and navigating standard FDA review process; Estimated 200,000 annual infusions[1]

Freedom360™ Next Gen Pump

Completed final stages of development process; 510(k) submission on track for 2H26

1. Third Party Data on File

Note: A detailed pipeline overview is available in the appendix and on KORU Medical's Corporate Presentation

Q2 2026 Results

Q2 Y/Y Revenue by Business: $12M+, 18% Growth

Net Revenues; In Millions



Domestic Core

- Increased 12% y/y
- Outpaced SCIg market growth
- Driven by new patient starts and market share gains
- Growth across all product lines

International Core

- Increased 59% y/y
- Growth in established markets
- PFS strategy in Europe

Pharma Services and Clinical Trials

- Decreased 35% y/y
- Lower orders for clinical trial use due to customer order timing

Q2 2026 Results

Gross Margin Guidance Raised On Continued Strength

Consistent Performance >60%



Gross Margin

- 160 basis point increase y/y
- Lower manufacturing costs resulting from production through-put efficiencies
- Higher average selling prices driven by price increase and customer mix
- Extended supply agreement with CMO securing favorable pricing and volume efficiencies

[1] *Refers to guidance range as of May 6, 2026*
[2] *Refers to updated guidance range as of August 5, 2026*

Q2 2026 Results

Cash Usage of ($0.5M): Positive CF from Operations

Cash Balance as of June 30, 2026: $8.3M



Key Drivers

- 2Q26 cash usage of $0.5M
- Positive cash flow from operations as net losses continue to decline
- Investing activities included purchase of technology assets and capital spend for building and equipment
- Non-cash primarily stock compensation, depreciation, and an asset disposal in the quarter

KORU

* Refer to appendix slide 3

Q2 2026 Results

1H 2026 Financial Highlights: Continued Demonstration of Operating Leverage and Disciplined Financial Profile

	1H 2026	1H 2025	Y/Y Δ
Revenue	$23.8M	$19.8M	+20% Growth
Gross Margin	63.3%	63.1%	+20bps
OpEx	$15.3M	$14.1M	+9% Increase
Net Loss	($0.6M)	($1.4M)	60% Improvement
Adj. EBITDA*	$0.9M	$0.02M	>1,000% Improvement
Cash Usage	($0.6M)	($1.5M)	62% Improvement

KORU

* Refer to appendix slide 3

2026 Outlook

Adjusting 2026 Guidance

Revenue Growth

$47.5-$48.5M, 15-18% growth

Key Drivers/Milestones

- Continued U.S. and international share gains in SCIg
- NRE revenue from ongoing and new collaborations
- 510(k) submission pending clearance
- Timing on international PFS conversion markets

Gross Margin Profile

62-64%
vs. prior range of 61-63%

Key Drivers/Milestones

- Pricing and manufacturing efficiencies implemented to improve gross margin profile with new supplier contract
- Revenue mix variability in new markets and channels
- Start up of new production line for next gen pumps (Freedom360™)

Profitability Metrics

Positive Adj. EBITDA & Year End Cash Balance > $7.5M

Key Drivers/Milestones

- Acquisition and related operating expenses for technology asset in Q2 and 2H respectively
- Q3 expected to be heaviest cash usage quarter
- Anticipated positive cash flow in Q4
- Ending Cash usage < $1.4M

2026 Outlook

Strategically Positioned for Accelerated Growth

Strong Fundamentals, Significant Opportunity[1]

Large and growing market for SC drug delivery; ~95 >10mL drugs in development

Leading share in U.S. SCIg, gaining momentum internationally

Recurring revenue from ~60,000 patients on platform

New strategic catalysts in SID and connected health technology

~8 non-Ig pipeline drugs with RYSTIGGO®[2] and deferoxamine as near-term commercial opportunities

Recent Accomplishments[1]

18% 2Q26 revenue growth over prior year period

2Q26 gross profit of $7.8M; gross margin 65.1%

2Q26 cash usage of ($0.5M); 17% y/y improvement

2Q26 Adj. EBITDA of $0.9M; 900% y/y improvement

Long Term Financial Goals[3]

$100M revenue

Accelerated double-digit revenue CAGR

>65% gross margins

+20% EBITDA margin

KORU

1. As of 2Q26 Earnings Press Release published on August 5th, 2026. 2. RYSTIGGO® cleared by FDA for use on Freedom Infusion System in 1Q26 3. Per most recent strategic plan

Q2 2026 Results

Consistent Execution and Key Strategic Progress

1. Q2 revenue of $12M represents growth of 18% over the prior year period
2. Net income improvement of 222% over the prior year period
3. Acquired a connected monitoring digital asset to potentially strengthen patient support infrastructure and generate real-time data insights for pharma partners
4. Q2 gross margin of 65.1%; full year 2026 gross margin guidance raised to 62-64%
5. Withdrew 510(k) application for use of the FreedomEDGE® with Phesgo® in favor of alternative oncology biologics with higher infusion volumes
6. Entered into an updated supplier agreement supporting long-term operational strategy and gross margin expansion
7. Narrowed full year 2026 revenue guidance to $47.5 - $48.5 million to account for PFS conversion market dynamics in Europe

Appendix

2026 Outlook

Execution Milestones on Path to Accelerated Revenue Growth

Adjusting 2026 Financial Guidance

- 15-18% revenue growth
- Positive Adjusted EBITDA, Cash of >$7.5M
- Gross margin 62-64%

Enable More Drugs, Reach More Patients

- Add 4 new pipeline collaborations for FY26: 2 of 4 complete
- ✔ Deferoxamine 510(k) submitted in Q1 2026

Expand Internationally

- ✔ Freedom60 EU MDR clearance with PFS compatibility
- Launch of Freedom Infusion System with PFS in targeted markets
- Exploring expansion of oncology strategy in international markets

Protect and Grow our Core Domestic Business

- New non-Ig drugs on label
  - ✔ UCB RYSTIGGO® 510(k) clearance in Jan 2026
- 510(k) submission Freedom360™ (2026)
- 510(k) and global submissions Phase 2 flow controller (2H 2026 - 1H 2027)

✔ Outpace SCIg market growth of 8-10%



Enabling New Drugs

Pipeline Opportunities in SCIg and New Drug Therapies

8 in Pipeline → **9 on Label**

Active Opportunities for New Drugs and Indications[1]

	Drug Asset	Annual Global Infusions Estimate[3]
Commercial — *Estimated KRMD Launch 0-1 Yr [1]*	Deferoxamine[2]	200k
	Phesgo[5]	600k
Phase III — *Estimated KRMD Launch 1-3 Yrs [1]*	Empaveli® FSGS + DGF[6]	25K + 25K
	Endocrinology Drug	500k
	Nephrology Drug	600k
Phases I & II — *Estimated KRMD Launch 3-5 Yrs [1]*	Respiratory Drug	1M
	ForCast Orthopedics	140k
	Multi-Indication Drug	2.4M

Represents ~5.5M total annual infusions worldwide

Drugs on KORU's Freedom Infusion System's Label

SCIg

5.4M[3] Annual Infusions

cutaquig® · HyQvia · Cuvitru · gammanorm® · Xembify® (immune globulin subcutaneous human-klhw) 20% · Hizentra® · GAMMAGARD LIQUID

6 Ig Collaborations for expanded indications and devices fuel share gains

Non-SCIg

<0.25M[3] Annual Infusions

ASPAVELI® ex U.S. · RYSTIGGO® · EMPAVELI® U.S.

2 Non-Ig Drugs broadening platform[4]

1. Clearance dates are based on most recent estimation and are subject to change, 2. KRMD pursuing drug label independently 3. Annual infusion figures are estimates based on total patient population and dosing schedule. Not adjusted for clinical risk, 4. Empaveli® is the U.S. brand name, outside of the U.S. the therapy is marketed as Aspaveli® 5. Reflects continued international pursuit of Phesgo® opportunity; 510(k) application for U.S. use has been withdrawn. 6. Subject to changes based on pending Biogen/Apellis integration strategy

Non-GAAP Financial Measures

This presentation includes the non-GAAP financial measures “adjusted EPS”, "adjusted diluted EPS“, and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on KORU Medical's reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company's financial results. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

Reconciliation of GAAP Net Income/(Loss) to Non-GAAP Adjusted EBITDA:	**Three Months Ended June 30,**		**Six Months Ended June 30,**	
	2026	**2025**	**2026**	**2025**
GAAP Net Income /(Loss)	$ 252,449	$ (206,867)	$ (554,628)	$ (1,373,104)
Depreciation and Amortization*	210,031	209,487	407,562	426,844
Interest (Income), Net	(59,870)	(78,951)	(140,866)	(152,130)
Stock-based Compensation Expense*	457,773	415,744	1,139,284	1,113,344
Adjusted EBITDA	$ 860,383	$ 339,414	$ 851,351	$ 14,953
Weighted Average Number Of Common Shares Outstanding				
Basic	46,083,893	46,193,709	46,223,623	46,088,353
Diluted	49,509,437	46,193,709	46,223,623	46,088,353

Reconciliation of Reported Diluted EPS to Non-GAAP Adjusted Diluted EPS:	**Three Months Ended June 30,**		**Six Months Ended June 30,**	
	2026	**2025**	**2026**	**2025**
Reported Diluted Earnings Per Share	$ 0.01	$ (0.00)	$ (0.01)	$ (0.03)
Depreciation and Amortization*	0.00	0.00	0.01	0.01
Interest (Income), Net	(0.00)	(0.00)	(0.00)	(0.00)
Stock-based Compensation Expense*	0.01	0.01	0.02	0.02
Adjusted Diluted Earnings Per Share	$ 0.02	$ 0.01	$ 0.02	$ 0.00

KORU * Non-cash items